Exposure to semaglutide appeared to be greater in the treatment arms that employed longer pre-dose fasting periods (Figs
It mimics the GLP-1 hormone to increase insulin release, reduce glucagon secretion, and slow stomach emptying
At the end of the trial, those in the liraglutide group achieved an average weight loss of 8.4 kg, compared to 2.8 kg in the placebo group, with a significant treatment difference of -5.6 kg (95% CI: -6.0 to -5.1
With both medications functioning as GLP-1 agonists, their main purpose is the same: aiding in weight loss by managing appetite and improving blood sugar control
Consistent blood sugar control is vital in preventing the complications associated with type 2 diabetes, such as nerve damage, kidney problems, and vision issues